OncoSec Medical Inc (ONCSQ)

[chickpea598]

That would be my guess. Because the 9 patients represent the pd-1 failure population and the rest of the trial patients are predicted non-responders from the bio-marker assay. The rest of the patients to be enrolled in this trial will also be failed pd-1 patients so this will be important data reported probably at the next Asco conference in June if they have data ready. The registration trial they are gearing up to do rides on this data because the registration trial will only enroll previously failed pd-1 patients.